OKYO Pharma Limited Sponsored ADR (OKYO) Price & Analysis

Compare

107 Followers

OKYO Stock Chart & Stats

$2.88

$0.09(7.75%)

At close: Jan 08 4:00 PM EST

$2.88

$0.09(7.75%)

Day’s Range― - ―

52-Week Range$0.90 - $3.35

Previous CloseN/A

Volume700.83K

Average Volume (3M)131.52K

Market Cap

$106.44M

Enterprise Value$48.59M

Total Cash (Recent Filing)$1.56M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.32

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding37,610,676

10 Day Avg. Volume47,624

30 Day Avg. Volume131,524

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-9.04

Price to Sales (P/S)0.00

P/FCF Ratio-27.67

Enterprise Value/Market Cap0.46

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-18.96K

Enterprise Value/Ebitda-6.86

Forecast

1Y Price Target

$6.00

Price Target Upside108.33% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyPhase 2 data showing a statistically significant reduction in mean pain scores for the urcosimod 0.05% group and a higher proportion of patients achieving greater than 50% pain improvement versus placebo reinforce the drug's efficacy signal and support commercial potential.

LeadershipAppointment of Robert J. Dempsey as chief executive officer and executive board member brings a proven track record in launching ophthalmic franchises and leading capital formation, potentially accelerating development and commercialization of the lead asset.

Mechanism And Unmet NeedObserved favorable changes in corneal nerve structure linked to chemerin receptor targeting indicate a possible disease‑modifying effect in neuropathic corneal pain, which currently lacks FDA‑approved therapies and could elevate the asset's strategic value.

Bears Say

OKYO Pharma Limited Sponsored ADR News

Okyo Pharma appoints Robery Dempsey as CEO

OKYO Pharma (OKYO) announced that, effective immediately, Robert Dempsey will assume the role of CEO. Gary Jacob, Ph.D....

12d ago

OKYO

OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on OKYO Pharma Limited Sponsored ADR today and set...

11d ago

OKYO

OKYO Pharma Names Ophthalmology Veteran Robert J. Dempsey as CEO to Drive Next Growth Phase

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has issued an update. On January 5, 2026, OKYO Pharma...

12d ago

OKYO

OKYO Pharma Rings Nasdaq Opening Bell as Urcosimod Advances After Positive Phase 2 NCP Data

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) just unveiled an announcement. On December 19, 2025, OKYO Pharma...

29d ago

OKYO

OKYO Pharma Chairman Increases Stake Amid Promising Drug Trials

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an update. On December 15, 2025, OKYO Pharma...

1M ago

OKYO

Okyo Pharma chairman acquires 24,551 company shares

OKYO Pharma (OKYO) has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive...

1M ago

OKYO

OKYO Pharma Reports Positive Phase 2 Results for Urcosimod in Neuropathic Corneal Pain

The latest announcement is out from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ). On December 11, 2025,...

1M ago

OKYO

Okyo Pharma’s urcosimod shows favorable corneal nerve outcomes in Phase 2 trial

Okyo Pharma (OKYO) announced new analyses of corneal images from the recently completed Phase 2 clinical trial of...

1M ago

OKYO

Okyo Pharma initiated with a Buy at B. Riley

B. Riley initiated coverage of Okyo Pharma (OKYO) with a Buy rating and $5 price target The firm...

1M ago

OKYO

OKYO Pharma’s Chairman Increases Stake Amidst Phase 2 Trial Completion

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has issued an update. On December 3, 2025, OKYO Pharma...

1M ago

OKYO

Okyo Pharma chairman acquires 27,051 company shares

OKYO Pharma (OKYO) announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a...

1M ago

OKYO

OKYO Pharma’s Chairman Increases Stake with Recent Share Acquisition

The latest update is out from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ). On November 21, 2025,...

2M ago

OKYO

Okyo Pharma chairman acquires 82,018 company shares

OKYO Pharma (OKYO) announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a...

2M ago

OKYO

OKYO Pharma to Present Urcosimod at OIS XV

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has issued an update. On November 18, 2025, OKYO Pharma...

2M ago

OKYO

OKYO FAQ

What was OKYO Pharma Limited Sponsored ADR’s price range in the past 12 months?

OKYO Pharma Limited Sponsored ADR lowest stock price was $0.90 and its highest was $3.35 in the past 12 months.

What is OKYO Pharma Limited Sponsored ADR’s market cap?

OKYO Pharma Limited Sponsored ADR’s market cap is $106.44M.

When is OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were OKYO Pharma Limited Sponsored ADR’s earnings last quarter?

Currently, no data Available

Is OKYO Pharma Limited Sponsored ADR overvalued?

According to Wall Street analysts OKYO Pharma Limited Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does OKYO Pharma Limited Sponsored ADR pay dividends?

OKYO Pharma Limited Sponsored ADR does not currently pay dividends.

What is OKYO Pharma Limited Sponsored ADR’s EPS estimate?

OKYO Pharma Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OKYO Pharma Limited Sponsored ADR have?

OKYO Pharma Limited Sponsored ADR has 37,610,676 shares outstanding.

What happened to OKYO Pharma Limited Sponsored ADR’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of OKYO Pharma Limited Sponsored ADR?

Currently, no hedge funds are holding shares in OKYO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

OKYO Pharma Limited Sponsored ADR Stock Smart Score

Neutral

Company Description

OKYO Pharma Limited Sponsored ADR

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited Sponsored ADR (OKYO) Earnings & Revenues

Historic Earnings Reports

OKYO Stock 12 Month Forecast

Average Price Target

$6.00

▲(108.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.449230769230769,2.8284615384615384,3.2076923076923074,3.5869230769230764,3.966153846153846,4.345384615384615,4.724615384615385,5.1038461538461535,5.483076923076922,5.8623076923076916,6.241538461538461,6.6207692307692305,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.3723076923076922,2.6746153846153846,2.976923076923077,3.279230769230769,3.581538461538462,3.8838461538461537,4.186153846153847,4.4884615384615385,4.7907692307692304,5.093076923076923,5.395384615384616,5.697692307692307,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.295384615384615,2.520769230769231,2.746153846153846,2.9715384615384615,3.1969230769230768,3.422307692307692,3.647692307692308,3.873076923076923,4.098461538461539,4.323846153846153,4.549230769230769,4.774615384615385,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.15,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >